Within three hours Nova Mentis stock under the ticker symbol CNSX: NOVA rockets after the company announced enrolling new patients for its North American autism study. The disease is not a new challenge for therapeutics-based firms but thorough research is still vital to fight the rare health issue. New Nova’s study will emphasize studying autism spectrum disorder (ASD) and fragile X syndrome (FXS).
After the study completes Nova Mentis will collect the data and process it through a machine learning platform so the researchers may know a clear picture to start their clinical trials using different candidates. The study may go on for months and the clinical trials as well.
CNSX: NOVA is still penny at $0.10 CAD, perhaps it may grow further slowly by crossing the $1 CAD mark. Investing in the stock is a direct contribution to fighting autism in North America.
About Nova Mentis
A Canadian-based biotechnology company and global leader in psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. Its mission is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder and fragile X syndrome. Nova is the first company to achieve psilocybin orphan drug designation in both the U.S. and European Union for the treatment of fragile X syndrome, the leading genetic cause of symptoms related to autism spectrum disorder. This provides the company with financial benefits, market exclusivity, research assistance, and access to grants.